DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Small EJ. et al.
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO 2020, Poster & Poster Discussion 5516.
J Clin Oncol 2020;
38 (Suppl. 15) 5516
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.